Hitting the Target in BRAF-Mutant Colorectal Cancer

J Clin Oncol. 2015 Dec 1;33(34):3990-2. doi: 10.1200/JCO.2015.63.7793. Epub 2015 Oct 12.

Authors

Ankur K Nagaraja¹, Adam J Bass²

Affiliations

¹ Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston; and Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, MA adam_bass@dfci.harvard.edu.

PMID: 26460302
DOI: 10.1200/JCO.2015.63.7793

No abstract available

Publication types

Editorial
Comment

MeSH terms

Animals
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Colorectal Neoplasms / drug therapy*
Female
Humans
Indoles / therapeutic use*
MAP Kinase Kinase 1 / antagonists & inhibitors*
Male
Mutation / genetics*
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics*
Skin Neoplasms / drug therapy*
Sulfonamides / therapeutic use*

Substances

Indoles
Sulfonamides
Proto-Oncogene Proteins B-raf
MAP Kinase Kinase 1